But my sense is that our industry's reflexive responses to negative findings are coming less from a place of concern for scientific integrity and more from a deeply held insecurity about A) the true efficacy of our products, B) the scientific provability of this efficacy and C) the economic impact that a negative trial
may have on a given product category.
Concern about a lack of external validity may discourage physicians from abandoning treatments following a negative trial
The point is, this was not a slam-dunk negative trial
, but it ended up getting reported that way.
A Glaxo SmithKline trial, study 329, which looked at the effects of the antidepressant paroxetine in depressed minors, was a negative trial
, but one that was published--sort of: Glaxo SmithKline published selected positive results.
The Canadian report also noted that "Monsanto pursued aggressive marketing tactics, compensated farmers whose veterinary bills escalated due to increased side effects associated with the use of [rBGH], and covered up negative trial
Panelists at the meeting said they were not comfortable drawing any conclusions from analyses of patient subgroups in a negative trial
Rather than being seen as a negative trial
, the study appears to speak to the usefulness of structured, individualized weekly CBT, said Dr.
For example, a recent negative study of saw palmetto for prostate problems was the first negative trial
out of more than 30 prior studies, all of which were more or less positive.
A fourth trial of approximately 400 patients with acute schizophrenia was considered a negative trial
, as the active-control (olanzapine) differentiated from placebo whereas asenapine did not.
In the wake of last year's nearly 2,000-patient negative trial
sponsored by the National Institutes of Health, this practice isn't routinely justified in all pregnancies.
com/research/146324/forecast_insight) has announced the addition of the "Forecast Insight: Dyslipidemia - Genericization and Negative Trial
Data Drive Market Shrinking" report to their offering.
The Panel's report concluded that: "In aggregate these deficiencies, and the fact that all relevant secondary end points were statistically significant in favour of AZD3582, do not allow a conclusion of negative trial